
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Hldgs is a promising investment opportunity due to a strong product portfolio and favorable market conditions. The recent 20% expansion of the sales force and positive legal developments have improved the revenue outlook for the company, with forecasted sales of $1.11B in 2026 and peak sales of $1.29B in 2029. Risks to the outlook include potential generic competition and legal challenges, but potential positive outcomes from clinical development of other drug candidates and improved patient adherence through next-generation treatments provide additional upside potential for the company.
Bears say
Harmony Biosciences Hldgs is currently facing challenges with its drug candidates in the pipeline as they still require further clinical trials and approvals, and its current commercial product, WAKIX, only holds a small market share. With a limited product portfolio, the company's financial performance is expected to be volatile and unpredictable, making it a risky investment. Additionally, the stock's recent significant increase may not be sustainable in the long term, as it may not reflect the company's underlying fundamental weaknesses.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares